WO2023042598A1 - X線不透過性充填材、歯科用x線不透過性充填材、x線不透過性充填材の製造方法、及び、歯科用硬化性組成物 - Google Patents
X線不透過性充填材、歯科用x線不透過性充填材、x線不透過性充填材の製造方法、及び、歯科用硬化性組成物 Download PDFInfo
- Publication number
- WO2023042598A1 WO2023042598A1 PCT/JP2022/031237 JP2022031237W WO2023042598A1 WO 2023042598 A1 WO2023042598 A1 WO 2023042598A1 JP 2022031237 W JP2022031237 W JP 2022031237W WO 2023042598 A1 WO2023042598 A1 WO 2023042598A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- rare earth
- ray opaque
- fluoride particles
- earth metal
- ray
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 120
- 239000000945 filler Substances 0.000 title claims abstract description 115
- 239000000463 material Substances 0.000 title claims abstract description 46
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 30
- 239000002245 particle Substances 0.000 claims abstract description 115
- 239000000843 powder Substances 0.000 claims abstract description 91
- -1 rare earth metal fluoride Chemical class 0.000 claims abstract description 89
- 229910052761 rare earth metal Inorganic materials 0.000 claims abstract description 85
- 239000000178 monomer Substances 0.000 claims abstract description 61
- 238000002441 X-ray diffraction Methods 0.000 claims abstract description 19
- 239000002994 raw material Substances 0.000 claims description 40
- 239000011164 primary particle Substances 0.000 claims description 29
- 238000011049 filling Methods 0.000 claims description 25
- 239000011324 bead Substances 0.000 claims description 21
- XASAPYQVQBKMIN-UHFFFAOYSA-K ytterbium(iii) fluoride Chemical compound F[Yb](F)F XASAPYQVQBKMIN-UHFFFAOYSA-K 0.000 claims description 12
- QCCDYNYSHILRDG-UHFFFAOYSA-K cerium(3+);trifluoride Chemical compound [F-].[F-].[F-].[Ce+3] QCCDYNYSHILRDG-UHFFFAOYSA-K 0.000 claims description 4
- TYIZUJNEZNBXRS-UHFFFAOYSA-K trifluorogadolinium Chemical compound F[Gd](F)F TYIZUJNEZNBXRS-UHFFFAOYSA-K 0.000 claims description 4
- BYMUNNMMXKDFEZ-UHFFFAOYSA-K trifluorolanthanum Chemical compound F[La](F)F BYMUNNMMXKDFEZ-UHFFFAOYSA-K 0.000 claims description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 3
- 238000012545 processing Methods 0.000 claims description 3
- 150000002910 rare earth metals Chemical class 0.000 claims description 3
- 229910052708 sodium Inorganic materials 0.000 claims description 3
- 239000011734 sodium Substances 0.000 claims description 3
- 229910001512 metal fluoride Inorganic materials 0.000 claims 1
- 230000007423 decrease Effects 0.000 abstract description 6
- 238000004381 surface treatment Methods 0.000 abstract description 2
- 238000010348 incorporation Methods 0.000 abstract 1
- 230000000052 comparative effect Effects 0.000 description 30
- 238000000034 method Methods 0.000 description 21
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 19
- 239000003505 polymerization initiator Substances 0.000 description 15
- 239000002002 slurry Substances 0.000 description 15
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 14
- 239000011163 secondary particle Substances 0.000 description 13
- 238000005259 measurement Methods 0.000 description 12
- 239000013078 crystal Substances 0.000 description 10
- 239000000126 substance Substances 0.000 description 10
- 230000000694 effects Effects 0.000 description 9
- MCMNRKCIXSYSNV-UHFFFAOYSA-N Zirconium dioxide Chemical compound O=[Zr]=O MCMNRKCIXSYSNV-UHFFFAOYSA-N 0.000 description 8
- 238000002156 mixing Methods 0.000 description 7
- 238000011156 evaluation Methods 0.000 description 6
- 238000006116 polymerization reaction Methods 0.000 description 6
- 239000000377 silicon dioxide Substances 0.000 description 6
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 5
- 238000009826 distribution Methods 0.000 description 5
- 229920005989 resin Polymers 0.000 description 5
- 239000011347 resin Substances 0.000 description 5
- 239000006087 Silane Coupling Agent Substances 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 239000002270 dispersing agent Substances 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 229910005690 GdF 3 Inorganic materials 0.000 description 3
- 229910017768 LaF 3 Inorganic materials 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 229910052782 aluminium Inorganic materials 0.000 description 3
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 3
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 3
- 239000005548 dental material Substances 0.000 description 3
- 230000006866 deterioration Effects 0.000 description 3
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 3
- 239000003999 initiator Substances 0.000 description 3
- 239000011256 inorganic filler Substances 0.000 description 3
- 229910003475 inorganic filler Inorganic materials 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 239000001294 propane Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000012756 surface treatment agent Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- VNQXSTWCDUXYEZ-UHFFFAOYSA-N 1,7,7-trimethylbicyclo[2.2.1]heptane-2,3-dione Chemical compound C1CC2(C)C(=O)C(=O)C1C2(C)C VNQXSTWCDUXYEZ-UHFFFAOYSA-N 0.000 description 2
- UEKHZPDUBLCUHN-UHFFFAOYSA-N 2-[[3,5,5-trimethyl-6-[2-(2-methylprop-2-enoyloxy)ethoxycarbonylamino]hexyl]carbamoyloxy]ethyl 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OCCOC(=O)NCCC(C)CC(C)(C)CNC(=O)OCCOC(=O)C(C)=C UEKHZPDUBLCUHN-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- AMFGWXWBFGVCKG-UHFFFAOYSA-N Panavia opaque Chemical compound C1=CC(OCC(O)COC(=O)C(=C)C)=CC=C1C(C)(C)C1=CC=C(OCC(O)COC(=O)C(C)=C)C=C1 AMFGWXWBFGVCKG-UHFFFAOYSA-N 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- 125000003647 acryloyl group Chemical group O=C([*])C([H])=C([H])[H] 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 229930006711 bornane-2,3-dione Natural products 0.000 description 2
- WERYXYBDKMZEQL-UHFFFAOYSA-N butane-1,4-diol Chemical compound OCCCCO WERYXYBDKMZEQL-UHFFFAOYSA-N 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- 239000011362 coarse particle Substances 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 238000007561 laser diffraction method Methods 0.000 description 2
- 239000012766 organic filler Substances 0.000 description 2
- 239000003973 paint Substances 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 229920001483 poly(ethyl methacrylate) polymer Polymers 0.000 description 2
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000004926 polymethyl methacrylate Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000000790 scattering method Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 238000012719 thermal polymerization Methods 0.000 description 2
- YWAKYZGTXSPLEN-UHFFFAOYSA-N (4-methyl-3-oxopent-4-enyl) N-[2,2,4-trimethyl-6-[(4-methyl-3-oxopent-4-enoxy)carbonylamino]hexyl]carbamate Chemical compound CC(CCNC(=O)OCCC(=O)C(C)=C)CC(C)(C)CNC(=O)OCCC(=O)C(C)=C YWAKYZGTXSPLEN-UHFFFAOYSA-N 0.000 description 1
- HWSSEYVMGDIFMH-UHFFFAOYSA-N 2-[2-[2-(2-methylprop-2-enoyloxy)ethoxy]ethoxy]ethyl 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OCCOCCOCCOC(=O)C(C)=C HWSSEYVMGDIFMH-UHFFFAOYSA-N 0.000 description 1
- VIYWVRIBDZTTMH-UHFFFAOYSA-N 2-[4-[2-[4-[2-(2-methylprop-2-enoyloxy)ethoxy]phenyl]propan-2-yl]phenoxy]ethyl 2-methylprop-2-enoate Chemical compound C1=CC(OCCOC(=O)C(=C)C)=CC=C1C(C)(C)C1=CC=C(OCCOC(=O)C(C)=C)C=C1 VIYWVRIBDZTTMH-UHFFFAOYSA-N 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- WGKYSFRFMQHMOF-UHFFFAOYSA-N 3-bromo-5-methylpyridine-2-carbonitrile Chemical compound CC1=CN=C(C#N)C(Br)=C1 WGKYSFRFMQHMOF-UHFFFAOYSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 1
- 229930182556 Polyacetal Natural products 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 244000028419 Styrax benzoin Species 0.000 description 1
- 235000000126 Styrax benzoin Nutrition 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 235000008411 Sumatra benzointree Nutrition 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- ZJCCRDAZUWHFQH-UHFFFAOYSA-N Trimethylolpropane Chemical compound CCC(CO)(CO)CO ZJCCRDAZUWHFQH-UHFFFAOYSA-N 0.000 description 1
- 229910009520 YbF3 Inorganic materials 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- XECAHXYUAAWDEL-UHFFFAOYSA-N acrylonitrile butadiene styrene Chemical compound C=CC=C.C=CC#N.C=CC1=CC=CC=C1 XECAHXYUAAWDEL-UHFFFAOYSA-N 0.000 description 1
- 239000004676 acrylonitrile butadiene styrene Substances 0.000 description 1
- 229920000122 acrylonitrile butadiene styrene Polymers 0.000 description 1
- 229920001893 acrylonitrile styrene Polymers 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 239000002280 amphoteric surfactant Substances 0.000 description 1
- 239000002216 antistatic agent Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 150000004982 aromatic amines Chemical class 0.000 description 1
- 229910052788 barium Inorganic materials 0.000 description 1
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
- 229960002130 benzoin Drugs 0.000 description 1
- 239000012965 benzophenone Substances 0.000 description 1
- 150000008366 benzophenones Chemical class 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- UIZLQMLDSWKZGC-UHFFFAOYSA-N cadmium helium Chemical compound [He].[Cd] UIZLQMLDSWKZGC-UHFFFAOYSA-N 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000013170 computed tomography imaging Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000007822 coupling agent Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 208000002925 dental caries Diseases 0.000 description 1
- ISAOCJYIOMOJEB-UHFFFAOYSA-N desyl alcohol Natural products C=1C=CC=CC=1C(O)C(=O)C1=CC=CC=C1 ISAOCJYIOMOJEB-UHFFFAOYSA-N 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- YPZCBIBAAUBMLB-UHFFFAOYSA-N ethyl 2,3-dimethylbenzoate Chemical compound CCOC(=O)C1=CC=CC(C)=C1C YPZCBIBAAUBMLB-UHFFFAOYSA-N 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 150000002222 fluorine compounds Chemical class 0.000 description 1
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 125000003055 glycidyl group Chemical group C(C1CO1)* 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 235000019382 gum benzoic Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- AVIYEYCFMVPYST-UHFFFAOYSA-N hexane-1,3-diol Chemical compound CCCC(O)CCO AVIYEYCFMVPYST-UHFFFAOYSA-N 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229910052809 inorganic oxide Inorganic materials 0.000 description 1
- 239000010954 inorganic particle Substances 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 229910052746 lanthanum Inorganic materials 0.000 description 1
- FZLIPJUXYLNCLC-UHFFFAOYSA-N lanthanum atom Chemical compound [La] FZLIPJUXYLNCLC-UHFFFAOYSA-N 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229910001507 metal halide Inorganic materials 0.000 description 1
- 150000005309 metal halides Chemical class 0.000 description 1
- 229910044991 metal oxide Inorganic materials 0.000 description 1
- 150000004706 metal oxides Chemical class 0.000 description 1
- 125000005395 methacrylic acid group Chemical group 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 229920000847 nonoxynol Polymers 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 229920000620 organic polymer Polymers 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 235000011837 pasties Nutrition 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 230000000379 polymerizing effect Effects 0.000 description 1
- 229920006324 polyoxymethylene Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- SCUZVMOVTVSBLE-UHFFFAOYSA-N prop-2-enenitrile;styrene Chemical compound C=CC#N.C=CC1=CC=CC=C1 SCUZVMOVTVSBLE-UHFFFAOYSA-N 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 239000010453 quartz Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 229910052712 strontium Inorganic materials 0.000 description 1
- CIOAGBVUUVVLOB-UHFFFAOYSA-N strontium atom Chemical compound [Sr] CIOAGBVUUVVLOB-UHFFFAOYSA-N 0.000 description 1
- 229920003048 styrene butadiene rubber Polymers 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- YRHRIQCWCFGUEQ-UHFFFAOYSA-N thioxanthen-9-one Chemical class C1=CC=C2C(=O)C3=CC=CC=C3SC2=C1 YRHRIQCWCFGUEQ-UHFFFAOYSA-N 0.000 description 1
- ZIBGPFATKBEMQZ-UHFFFAOYSA-N triethylene glycol Chemical compound OCCOCCOCCO ZIBGPFATKBEMQZ-UHFFFAOYSA-N 0.000 description 1
- WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical compound [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 description 1
- 229910052721 tungsten Inorganic materials 0.000 description 1
- 239000010937 tungsten Substances 0.000 description 1
- 238000007740 vapor deposition Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 229910052724 xenon Inorganic materials 0.000 description 1
- FHNFHKCVQCLJFQ-UHFFFAOYSA-N xenon atom Chemical compound [Xe] FHNFHKCVQCLJFQ-UHFFFAOYSA-N 0.000 description 1
- 229910052845 zircon Inorganic materials 0.000 description 1
- GFQYVLUOOAAOGM-UHFFFAOYSA-N zirconium(iv) silicate Chemical compound [Zr+4].[O-][Si]([O-])([O-])[O-] GFQYVLUOOAAOGM-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K6/00—Preparations for dentistry
- A61K6/25—Compositions for detecting or measuring, e.g. of irregularities on natural or artificial teeth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K6/00—Preparations for dentistry
- A61K6/15—Compositions characterised by their physical properties
- A61K6/16—Refractive index
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K6/00—Preparations for dentistry
- A61K6/70—Preparations for dentistry comprising inorganic additives
- A61K6/71—Fillers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K6/00—Preparations for dentistry
- A61K6/80—Preparations for artificial teeth, for filling teeth or for capping teeth
- A61K6/84—Preparations for artificial teeth, for filling teeth or for capping teeth comprising metals or alloys
Definitions
- the present invention relates to a radiopaque filling material, a radiopaque dental filling material, a method for producing the radiopaque filling material, and a curable dental composition.
- a dental filling material In dental treatment, after caries has been removed, the cavity is filled with a dental filling material, which is then hardened to close the cavity with a hardening material.
- a dental filling material a curable composition containing a polymerizable monomer, a filler, and a polymerization initiator as main components is generally used.
- Inorganic oxide fillers particularly silica-based fillers, are generally used as fillers to be blended in this curable composition.
- silica-based fillers have low radiopacity. For this reason, during X-ray imaging and CT imaging during dental treatment, the hardened material in the cavity is not imaged, making it difficult to determine the treated area.
- Patent Document 1 A radiopaque dental material based on a polymerizable organic binder, a radiopaque component, and an optional inorganic filler, and, as the radiopaque component, a fluoride of a rare earth metal of the periodic system of the elements (element numbers 57-71) or a mixture of these fluorides in an amount of 1-50% by weight, based on the total weight Radiopaque dental restoratives containing" are described.
- the present invention provides an X-ray opaque filling material capable of imparting the necessary X-ray opacity to a dental curable composition, hardly reducing the permeability of the cured product, and enabling aesthetic restoration.
- the present invention provides a dental radiopaque filling material comprising the radiopaque filling material, a method for producing the radiopaque filling material, and a method for producing the radiopaque filling material.
- An object of the present invention is to provide a dental curable composition having a
- the term "cured body” simply means a cured body of a curable composition or a dental curable composition, and a cured body obtained by curing a polymerizable monomer. is referred to as a "cured polymerizable monomer".
- a first form of the present invention is a curable composition containing a polymerizable monomer and a cured product thereof by adding X-rays to the curable composition and its cured body.
- An X-ray opaque filler that imparts opacity, comprising crystalline rare earth metal fluoride particles as a major component, and having an intensity maximum from said crystalline rare earth metal fluoride particles in an X-ray diffraction pattern.
- a first powder having a peak full width at half maximum hereinafter also referred to as "maximum peak half width" of 0.3° or more, and a second powder obtained by surface-treating the first powder.
- An X-ray opaque filler characterized by comprising any powder selected from the group.
- the first powder is an average primary particle measured by an electron microscope At least one selected from the group consisting of crystalline rare earth metal fluoride particles having a diameter of 5 to 300 nm and agglomerated particles of crystalline rare earth metal fluoride particles having an average primary particle diameter of 1 to 500 nm.
- a powder containing particles as a main component is preferred.
- the crystalline rare earth metal fluoride particles are preferably crystalline ytterbium fluoride particles.
- the crystalline rare earth metal fluoride particles preferably contain at least one particle selected from the group consisting of crystalline lanthanum fluoride particles, crystalline cerium fluoride particles, and crystalline gadolinium fluoride particles. .
- the full width at half maximum is preferably 0.77° or less.
- the full width at half maximum is preferably 0.47° to 0.68°.
- the full width at half maximum is preferably 0.51° to 0.59°.
- a second aspect of the present invention is a radiopaque dental filling material comprising the radiopaque filling material of the present invention (hereinafter referred to as "the radiopaque dental filling material of the present invention"). It is also called “material”.).
- a third aspect of the present invention is a method for producing the X-ray opaque filler of the present invention, comprising crystalline rare earth metal fluoride particles as a main component, and said crystalline rare earth metal fluoride particles A raw material powder having a maximum peak half-value width of less than 0.3 ° derived from A method for manufacturing a filler.
- the mechanochemical treatment is a wet bead mill treatment.
- a fourth aspect of the present invention is a dental curable composition comprising a polymerizable monomer and the X-ray opaque filler of the present invention.
- the crystalline rare earth metal fluoride particles are crystalline ytterbium fluoride particles
- the cured product of the polymerizable monomer has a refractive index of 1.45 to 1.60 with respect to the sodium d-line at 25°C.
- the radiopaque filling material of the present invention and the dental radiopaque filling material of the present invention contain a polymerizable monomer, unlike conventional radiopaque filling materials made of rare earth metal fluorides.
- the transparency of the cured product is less likely to be lowered even if the blending amount is increased. Therefore, by using the dental curable composition of the present invention containing the X-ray opaque filler of the present invention, it is possible to perform treatment that is excellent in aesthetics and allows the treated area to be easily confirmed by an X-ray photograph or the like. .
- the X-ray opaque filler of the present invention can be used not only in dental applications but also in polymerizable curable compositions for various applications such as adhesives and paints, and the transparency and X-ray opacity of the cured product can be improved. can be achieved. Furthermore, according to the manufacturing method of the present invention, the X-ray opaque filler of the present invention having the above-described excellent features can be efficiently manufactured using readily available materials.
- This figure shows the relationship between the maximum peak half width of the crystalline rare earth metal fluoride particles contained in the X-ray opaque filler and the contrast ratio of the cured product for Examples 1 to 11 and Comparative Examples 1 to 4. graph.
- This figure shows the mechanochemical treatment time and X-ray impermeability of the raw material powder (crystalline rare earth metal fluoride particles) used in the production of the X-ray opaque filler for Examples 1 to 11 and Comparative Examples 1 to 4.
- 4 is a graph showing the relationship between the maximum peak half-value width of crystalline rare earth metal fluoride particles contained in a permeable filler.
- This figure shows the mechanochemical treatment time of the raw material powder (crystalline rare earth metal fluoride particles) used in the production of the X-ray opaque filler and the cured product for Examples 1 to 11 and Comparative Examples 1 to 4. 4 is a graph showing the relationship with contrast ratio.
- This figure shows the mechanochemical treatment time and X-ray impermeability of the raw material powder (crystalline rare earth metal fluoride particles) used in the production of the X-ray opaque filler for Examples 1 to 11 and Comparative Examples 1 to 4. 4 is a graph showing the relationship between the average primary particle size of crystalline rare earth metal fluoride particles contained in a permeable filler and the average primary particle size.
- This figure shows the relationship between the refractive index of the polymerizable monomer or the cured product of the polymerizable monomer and the contrast ratio of the curable composition or the cured product for Examples 16 to 22 and Comparative Examples 7 to 13. It is a graph showing. This figure shows the relationship between the refractive index of the polymerizable monomer or the cured product of the polymerizable monomer and the contrast ratio of the curable composition or the cured product for Examples 23 to 29 and Comparative Examples 14 to 20. It is a graph showing. This figure shows the relationship between the refractive index of the polymerizable monomer or the cured product of the polymerizable monomer and the contrast ratio of the curable composition or the cured product for Examples 30 to 36 and Comparative Examples 21 to 27.
- the present inventors have found the above-mentioned problem of conventional X-ray opaque fillers composed of rare earth metal fluorides, that is, when blended in a curable composition containing a polymerizable monomer, curing when the amount is increased Intensive studies were conducted to solve the problem that the transparency of the body is greatly reduced. As a result, the present inventors happened to find a powder obtained by subjecting crystalline ytterbium fluoride, known as an X-ray opaque filler, to mechanochemical treatment for a long period of time using a wet bead mill. is used, the transparency of the cured product is less likely to decrease even if the blending amount is increased.
- the mechanochemical treatment reduces the crystallinity of the crystal grains.
- the crystallinity of the crystal grains is grasped by the full width at half maximum (maximum peak half width) of the maximum intensity peak derived from crystalline ytterbium fluoride in the diffraction pattern obtained by X-ray diffraction measurement of the powder. Even in a state in which the powder is hardly finely divided, when the degree of crystallinity deterioration exceeds a certain level, an effect of preventing deterioration in transparency can be obtained.
- the reason why the effect of the X-ray opaque filling material of the present invention is exhibited is presumed to be as follows.
- the decrease in transparency in a system in which inorganic fine particles are dispersed in a resin matrix is greatly influenced by diffuse reflection of light at the interface between the two.
- the vicinity of the surface of the crystalline rare earth metal fluoride particles is gradually made amorphous from the surface toward the inside by the mechanochemical treatment. Therefore, in the vicinity of the surface of the crystalline rare earth metal fluoride particles, a layer in which the refractive index gradually decreases with a constant gradient from the inside toward the surface (hereinafter also referred to as "gradient refractive index layer”) is formed.
- gradient refractive index layer a layer in which the refractive index gradually decreases with a constant gradient from the inside toward the surface
- the formed refractive index gradient layer includes a portion having a refractive index that matches the refractive index of the resin matrix.
- the proportion of reflected light is reduced (the proportion of transmitted light is increased), and deterioration of transparency is suppressed.
- the X-ray opaque filler of the present invention is added to the curable composition and its cured product by blending with the curable composition containing a polymerizable monomer. It is a radiopaque filler that provides radiopacity.
- the polymerizable monomer contained in the curable composition which is the object to be imparted with X-ray opacity, is not particularly limited as long as it is a polymerizable compound, and those commonly used depending on the application are used. can.
- the curable composition is a dental curable composition
- radically polymerizable monomers and the like commonly used in the application can be used.
- the polymerizable monomer used in the curable composition to be blended with the X-ray opaque filler of the present invention has a refractive index difference of “n X ⁇ n M ” is preferably within a specific range.
- n X means the refractive index of the crystalline rare earth metal fluoride particles that are the main component of the X-ray opaque filler of the present invention
- n M means the refractive index of the cured polymerizable monomer. means rate.
- the mechanochemically treated crystalline rare earth metal fluoride particles are presumed to have a refractive index gradient layer near the surface as described above. However, since the ratio of the gradient refractive index layer to the entire mechanochemically treated crystalline rare earth metal fluoride particles is very small, the presence or absence of the gradient refractive index layer does not substantially affect the refractive index of the entire particle. Conceivable. The inventors also confirmed that there is substantially no significant difference in the refractive index of the crystalline rare earth metal fluoride particles before and after the mechanochemical treatment.
- the X-ray opaque filler of the present invention comprises a first powder containing crystalline rare earth metal fluoride particles as a main component and having a maximum peak half width of 0.3° or more in an X-ray diffraction pattern; And, it must be composed of any powder selected from the group consisting of the second powder obtained by surface-treating the first powder. Even with a powder containing crystalline rare earth metal fluoride particles as a main component, if the maximum peak half width in the X-ray diffraction pattern is less than 0.3°, it is difficult to obtain the effect of preventing opacification.
- the powder constituting the X-ray opaque filler of the present invention is simply referred to as "powder" when the first powder and the second powder are not distinguished from each other.
- Components other than the crystalline rare earth metal fluoride particles include (i) a substance derived from a surface treatment agent such as a silane coupling agent, or (ii) used in the raw material powder in the production method of the present invention, which will be described later. Coating agents such as silica, surface treatment agents such as silane coupling agents, or substances derived from other trace additives used as necessary.
- "contains crystalline rare earth metal fluoride particles as a main component” means that 85% by mass or more of the total mass of the powder is composed of crystalline rare earth metal fluoride particles. In this case, 90 mass % or more of the total mass of the powder is preferably composed of crystalline rare earth metal fluoride particles.
- the crystalline rare earth metal fluoride particles that constitute the main component of the powder and the maximum peak half width will be described in detail below.
- Crystalline Rare Earth Metal Fluoride Particles As rare earth metal fluorides in the crystalline rare earth metal fluoride particles, lanthanum fluoride (LaF 3 ), cerium fluoride (CeF 3 ), ytterbium fluoride (YbF) are selected from their color tone and safety. 3 ), or gadolinium fluoride (GdF 3 ) is preferably used, and ytterbium fluoride (YbF 3 ) is most preferably used from the viewpoint of X-ray opacity.
- the crystal structure of the crystalline rare earth metal fluoride particles is not particularly limited, and usually, those having a stable crystal structure at normal temperature and normal pressure are used according to the type of rare earth metal fluoride.
- the refractive index of these crystalline rare earth metal fluorides for sodium d-line at 25° C. is usually in the range of 1.50 to 1.65.
- the first powder has an average primary particle size of 1 to 500 nm as measured by electron microscopic observation, from the viewpoint of the effect of maintaining transparency and the glossiness of the cured product when blended in the dental curable composition. It preferably contains crystalline rare earth metal fluoride particles and/or aggregated particles thereof as a main component. In this case, the average primary particle diameter of the crystalline rare earth metal fluoride particles is particularly preferably 5 to 300 nm.
- the primary particle diameter measured by the electron microscope observation means that the primary particles in the observation image obtained by observing at a magnification of 100,000 times using a scanning electron microscope (SEM) means the average value of the particle diameters of individual particles.
- the average particle size (of the entire powder including aggregated particles) measured by a laser diffraction/scattering method is preferably 0.1 to 0.6 ⁇ m, particularly 0.1 It is preferably ⁇ 0.3 ⁇ m.
- the maximum half-value width of the peak in order to obtain the effect of preventing opacification, the maximum half-value width of the peak, that is, the crystalline rare earth metal fluoride particles in the X-ray diffraction pattern of the powder
- the full width at half maximum of the maximum intensity peak derived from must be 0.3° or more.
- the maximum peak half width is preferably 0.4° or more, and particularly preferably 0.5° or more.
- the upper limit of the maximum peak half width is not particularly limited, it usually does not exceed 40°.
- the maximum peak half width is preferably 0.77° or less, based on Table 1 described later.
- the maximum peak half width is preferably 0.47° to 0.68°, and 0.51°. ⁇ 0.59° is more preferred.
- the maximum peak half width in the present invention can be determined by performing X-ray diffraction measurement on the powder that becomes the X-ray opaque filler of the present invention. Specifically, by performing X-ray diffraction measurement of a measurement sample (powder) in the range of 20 to 120 ° with an X-ray diffractometer, the horizontal axis is 2 ⁇ (°) and the vertical axis is diffraction intensity. Obtain the X-ray diffraction pattern (chart) shown. Thereby, the peaks derived from the crystalline rare earth metal fluoride particles are identified, and the peak having the maximum intensity among them is specified.
- the peak width at an intensity that is 50% of the maximum intensity (50% intensity) at the peak having the maximum intensity is obtained as the maximum peak half width.
- the peak width is the absolute value of the difference in 2 ⁇ between two intersections of the peak line and a straight line parallel to the horizontal axis of the X-ray diffraction pattern (chart) and at the position of 50% intensity ( The unit is “deg [°]”).
- the maximum peak half-value width increases with the length of the treatment time even in a system in which the primary particle diameter is originally small and the primary particle diameter does not change even if the treatment time is lengthened. It is considered that the crystallinity in the sample is non-uniform. However, it is difficult to analyze the state of the crystallites and the state of distortion of the crystal lattice for the individual crystalline rare earth metal fluoride particles that constitute the powder that becomes the X-ray opaque filler of the present invention. , is practically impossible.
- the radiopaque filler of the present invention is specified using the maximum peak half width as an index of averaged crystallinity.
- the X-ray-opaque filler of the present invention can also be said to be the X-ray-opaque filler obtained by the production method of the present invention.
- the production method of the present invention is a method for producing the X-ray opaque filler of the present invention, which contains crystalline rare earth metal fluoride particles as a main component and has a maximum peak half width of is less than 0.3°, and mechanochemically treats the raw material powder so that the maximum peak half width is 0.3° or more.
- the maximum peak half width of the (crystalline) rare earth metal fluoride powders available as rare earth metal fluoride-based X-ray opaque fillers and reagents generally used in the past is usually less than 0.3°. Therefore, such a powder can be used as the raw material powder without any particular limitation. If there is concern that the crystallinity of the raw material powder is low, perform X-ray diffraction measurement of the raw material powder and confirm that the maximum peak half width is less than 0.3° before use. is preferred.
- the commercially available crystalline rare earth metal fluoride powders for X-ray opaque fillers include powders surface-coated with nanosilica and powders surface-treated with a silane coupling agent or the like.
- these powders can be used as raw material powders as they are.
- the particles are pulverized, the secondary particles (aggregated particles) and primary particles are crushed, and the particle size of the raw material powder is reduced.
- mechanochemical treatment for several hours does not significantly change the particle size of the raw material powder.
- the raw material powder has an average primary particle diameter of 1 as measured by electron microscope observation (similar to the powder constituting the X-ray opaque filler of the present invention).
- It is preferably ⁇ 500 nm, particularly preferably 5 to 300 nm, and preferably has an average particle size of 0.1 to 0.6 ⁇ m, particularly 0.1, as measured by a laser diffraction/scattering method. It is preferably ⁇ 0.3 ⁇ m.
- the raw material powder is subjected to mechanochemical treatment so that the maximum peak half width is 0.3° or more.
- the mechanochemical treatment means a treatment that applies mechanical energy to the raw material powder, and means a treatment that performs at least one of mechanical grinding, pulverization, and dispersion. It is preferable to adopt a wet method as a mechanochemical treatment method because the crystallinity of the crystalline rare earth metal fluoride powder (or particles) can be reliably and efficiently controlled to the desired crystallinity. A processing method using a wet bead mill is particularly preferred.
- a medium such as a solvent such as water or alcohol, or a polymerizable monomer can be used as the medium.
- the medium is preferably liquid at room temperature (15 to 25°C).
- the slurry which is a mixture of the raw material powder to be mechanochemically treated and the medium, is brought into contact with the media (beads) that have been moved by stirring or vibration. Thereby, the raw material powder is pulverized and crushed.
- Materials for the beads used as media include glass, alumina, zircon, zirconia, steel, resin, and the like. Alumina and zirconia are preferred because of their excellent wear resistance and relatively low contamination. preferable.
- the size of the beads to be used may be selected according to the particle size of the desired X-ray opaque filler, but there is no particular limitation, but it is usually preferable to use beads with a diameter of 0.01 mm to 0.5 mm. This makes it possible to obtain a radiopaque filler with a preferred particle size for addition to dental curable compositions.
- a batch type in which slurry and beads are directly charged into the device for processing
- a circulation type in which the slurry circulates between the tank and the device
- a pass type in which the slurry passes through the device a predetermined number of times.
- These operation methods may be selected according to the amount of raw material powder used in the mechanochemical treatment.
- a circulating bead mill is preferably used because it has good productivity and can process a relatively large amount of raw material powder.
- the bead separation method include a slit method, a screen method, a centrifugal method, and the like. These bead separation methods may be selected according to the particle size of the beads used, and any method can be used without particular limitation.
- the concentration of the slurry used in the mechanochemical treatment is preferably 50 parts by mass or less of the raw material powder per 100 parts by mass of the medium. If the amount of the raw material powder in the slurry exceeds 50 parts by mass, the viscosity of the slurry increases, which may make the mechanochemical treatment difficult.
- any known surfactant that is commonly used for dispersing treatment of fillers can be used without particular limitation.
- examples include active agents, amphoteric surfactants, and polymeric surfactants thereof.
- Specific examples include glycerol fatty acid esters and alkylene glycol adducts thereof, aliphatic monocarboxylates, alkylamine salts, and alkylbetaines.
- a dental curable composition using a mechanochemically treated raw material powder (crystalline rare earth metal fluoride particles having a maximum peak half width of 0.3 ° or more), in the dental curable composition From the viewpoint of the dispersibility of the raw material powder after the mechanochemical treatment of (1), it is preferable to use a cationic surfactant as the dispersant.
- the mechanochemical treatment conditions vary depending on the operation method of the wet bead mill equipment used, the bead diameter, the maximum peak half width of the raw material powder, and the concentration of the slurry. These conditions can be determined by performing a preliminary experiment using an apparatus that actually performs the mechanochemical treatment, and confirming the maximum peak half width of the raw material powder after the mechanochemical treatment with respect to the mechanochemical treatment time. In addition, during the production of the X-ray opaque filler, the treated slurry is sampled as necessary to appropriately confirm the maximum peak half-value width. As a result, it is possible to reliably produce an X-ray opaque filler containing crystalline rare earth metal fluoride particles as a main component having a desired maximum peak half-value width.
- the raw material powder (mechanochemically treated crystalline rare earth metal fluoride particles) having a maximum peak half width of 0.3° or more by mechanochemical treatment is usually subjected to operations such as concentration, drying, and filtration.
- a radiopaque filler according to the invention is obtained.
- a polymerizable monomer is used as a medium in wet processing, it can be used as it is without performing these operations.
- the obtained X-ray opaque filler can be subjected to a surface treatment to improve affinity with various polymerizable monomers and polymers thereof.
- Compounds such as silane coupling agents and titanate coupling agents that are generally used can be used as the surface treatment agent.
- the radiopaque filler of the present invention is a filler compounded in a dental curable composition (i.e., a dental radiopaque It is particularly useful as a flexible filler).
- the curable dental composition contains a polymerizable monomer and a polymerization initiator in addition to the X-ray opaque filler of the present invention.
- polymerizable monomer known ones used for the purpose can be used without limitation. Specific examples include methyl (meth) acrylate, glycidyl (meth) acrylate, 2-cyanomethyl (meth) acrylate, polyethylene glycol mono (meth) acrylate, allyl (meth) acrylate, 2-hydroxyethyl mono (meth) acrylate.
- a polymerizable monomer can be used individually or in combination of 2 or more types.
- the polymerizable monomer has a refractive index difference “n X ⁇ n M ” within a specific range as described above. Specifically, it preferably satisfies formula (1), more preferably satisfies formula (2), and most preferably satisfies formula (3).
- the refractive index of the cured product of the polymerizable monomer can be adjusted by combining a plurality of polymerizable monomers, and the known polymerizable monomers can be used by mixing at any ratio.
- the amount of the X-ray opaque filler of the present invention to be blended in the curable dental composition of the present invention is not particularly limited as long as the curable dental composition becomes paste-like. It is preferably in the range of 1 to 80 parts by mass, more preferably in the range of 3 to 70 parts by mass, based on 100 parts by mass of the curable dental composition. Furthermore, from the viewpoint of imparting X-ray opacity to the cured body and various physical properties (e.g., mechanical strength and hardness), the amount of the X-ray opaque filler blended with respect to 100 parts by mass of the dental curable composition is It is more preferably 10 to 40 parts by mass. From the viewpoint of imparting X-ray opacity to the cured product, it is also preferable to blend 1 to 400 parts by mass of an X-ray opaque filler with respect to 100 parts by mass of the polymerizable monomer.
- polymerization initiator chemical polymerization initiators, photopolymerization initiators, thermal polymerization initiators, etc., which are used as polymerization initiators capable of polymerizing polymerizable monomers, can be used without particular limitation. .
- the amount of the polymerization initiator to be blended is not particularly limited as long as it is an amount capable of initiating polymerization, but it is usually in the range of 0.001 to 10 parts by mass with respect to 100 parts by mass of the polymerizable monomer. From the viewpoint of the polymerization rate and various physical properties (eg, weather resistance and hardness) of the resulting cured product, it is preferable to blend 0.05 to 5 parts by mass based on the above criteria.
- the type of polymerization initiator may be selected depending on the use of the dental curable composition.
- the dental hardenable composition is a dental filling and restorative material that hardens in the oral cavity
- a thermal polymerization initiator when a bulk body obtained by pre-curing a dental curable composition is cut in a dental clinic, a laboratory, or the like to be used as a mill blank, it is preferable to use a thermal polymerization initiator.
- photopolymerization initiators examples include benzoin alkyl ethers, benzyl ketals, benzophenones, ⁇ -diketones, thioxanthone compounds, and bisacylphosphine oxides.
- a reducing agent is often added to the photopolymerization initiator.
- reducing agents include aromatic amines, aliphatic amines, aldehydes, and sulfur-containing compounds.
- trihalomethyltriazine compounds, aryliodonium salts and the like can be added as necessary.
- the dental curable composition of the present invention may contain other components known as components of dental curable compositions, particularly dental filling and restorative materials.
- Such components include fillers other than the X-ray opaque filler of the present invention, polymerization inhibitors, ultraviolet absorbers, dyes, antistatic agents, pigments, fragrances, organic solvents, and thickeners. known additives.
- organic fillers examples include polymethyl methacrylate, polyethyl methacrylate, methyl methacrylate-ethyl methacrylate copolymer, crosslinked polymethyl methacrylate, crosslinked polyethyl methacrylate, ethylene-vinyl acetate copolymer, styrene-butadiene copolymer, Particles made of organic polymers such as acrylonitrile-styrene copolymers and acrylonitrile-butadiene-styrene copolymers can be mentioned.
- inorganic fillers include inorganic particles such as quartz, silica, alumina, silica titania, silica zirconia, lanthanum glass, barium glass, strontium glass, and metal oxides.
- the particle size and shape of these other fillers are not particularly limited, and spherical or amorphous particles having an average particle size of 0.001 ⁇ m to 100 ⁇ m, which are generally used as dental materials, are used depending on the purpose. It can be used appropriately.
- the refractive index of these other fillers is not particularly limited, and those in the range of 1.4 to 2.6 that general dental curable composition fillers have can be used without limitation.
- the amount of other fillers added to the curable composition for dental use is also not particularly limited as long as the curable composition for dental use becomes a paste. However, when the dental curable composition is used as a dental filling and restorative material, the total amount of the X-ray opaque filler and other fillers is It is preferably 25 to 400 parts by mass, more preferably 40 to 250 parts by mass.
- the curable composition blended with the X-ray opaque filler of the present invention is not limited to the above-described dental uses, and can be used for adhesives, paints, optical materials, etc. In particular, it can be used as a dental filling and restorative material. It is preferred to use as
- the method for producing the dental curable composition of the present invention is not particularly limited, and any known method for producing a curable composition may be employed as appropriate. Specifically, (i) in the dark in the case of a photopolymerizable dental curable composition, or (ii) in the case of a thermally polymerizable dental curable composition, at room temperature or at a low temperature. , Weighing a predetermined amount of the X-ray opaque filler, the polymerizable monomer, the polymerization initiator, and other optional ingredients that constitute the dental curable composition of the present invention, A paste-like curable dental composition may be prepared by mixing these. The curable dental composition of the present invention thus produced is stored in the dark, at room temperature, or at a low temperature until use.
- the above photopolymerized or thermally polymerized dental curable composition is added in a state in which two or more components that generate active species when mixed are physically separated. It is manufactured and stored in the same manner as the composition.
- known polymerization means may be employed as appropriate according to the polymerization initiation mechanism of the polymerization initiator used.
- a curing means light irradiation from a light source such as carbon arc, xenon lamp, metal halide lamp, tungsten lamp, fluorescent lamp, sunlight, helium cadmium laser, argon laser, etc., or using a heat polymerization device, etc. Heating, a method combining these methods, or the like can be used without any limitation.
- the irradiation time varies depending on the wavelength/intensity of the light source, the shape and material of the cured product, and may be determined in advance by preliminary experiments. Generally, however, it is preferable to adjust the mixing ratio of the various components contained in the dental curable composition so that the irradiation time is in the range of about 5 to 60 seconds.
- the average primary particle size of the crystalline rare earth metal fluoride particles constituting the X-ray opaque filler was determined by the following procedure using a scanning electron microscope. First, after fixing an X-ray opaque filler on a sample table with carbon paste, a measurement sample was prepared by subjecting it to a conductive treatment (platinum vapor deposition). Next, this measurement sample was observed with an electron microscope (JSM-7800F PRIME, manufactured by JEOL Ltd.) at a magnification of 100,000 times, and the average particle of 100 primary particles in the observed image obtained The diameter was obtained as an average primary particle diameter. Also, the average primary particle size of the raw material powder was obtained by the same procedure.
- the average secondary particle size of the crystalline rare earth metal fluoride particles constituting the X-ray opaque filler was determined by the following procedure by particle size distribution measurement. First, a suspension was prepared by suspending 0.1 g of powder (X-ray opaque filler) in 10 mL of deionized water. Next, while the suspension was irradiated with ultrasonic waves, the particle size distribution was measured using a particle size distribution meter (LS13-320, manufactured by BECKMAN COULTER) to obtain the volume particle size distribution. The average secondary particle size of the crystalline rare earth metal fluoride particles constituting the X-ray opaque filler was defined as the cumulative 50% particle size (D50v value) from the small size side of the volume particle size distribution. Also, the average secondary particle size of the raw material powder was obtained by the same procedure.
- refractive index 2-3-1 Refractive index n 0 of the polymerizable monomer
- refractive index n 0 of the polymerizable monomer used in the preparation of the curable composition was measured at 25 ° C. using an Abbe refractometer (DR-A1-Plus, manufactured by Atago Co., Ltd.). measured as a percentage.
- Refractive index nM of polymer (cured polymerizable monomer) Polymerizable monomers used in the preparation of the curable composition (provided that trace amounts of polymerization initiators (0.2% by weight of camphorquinone and 0.35% by weight of N,N-dimethyl-p -ethyl benzoate) was filled into the through-hole (diameter 7 mm, through-hole length 0.5 mm) provided in the mold, and then the openings on both sides of the through-hole were sealed while being pressed with a polypropylene film. .
- the polymerizable monomer filled in the through-holes is cured by light irradiation for 30 seconds using a halogen-type dental light irradiation device (Demetron LC, manufactured by Sypron Co., Ltd.) with a light intensity of 500 mW/cm 2 . let me Thereafter, the refractive index nM of the cured polymerizable monomer removed from the mold was measured in the same manner as in 2-3-1.
- a halogen-type dental light irradiation device (Demetron LC, manufactured by Sypron Co., Ltd.) with a light intensity of 500 mW/cm 2 .
- Refractive index n X of crystalline rare earth fluoride particles In a constant temperature room at 25° C., 1 g of crystalline rare earth fluoride particles was suspended in 50 mL of anhydrous toluene in a 100 mL sample bottle. While stirring this suspension with a stirrer, 1-bromotoluene was added dropwise little by little, and the refractive index of the suspension when it became most transparent was measured in the same manner as in 2-3-1. , the obtained value was defined as the refractive index nX of the crystalline rare earth fluoride particles. As described above, the refractive index nX of the crystalline rare earth fluoride particles after the mechanochemical treatment was substituted by the refractive index of the crystalline rare earth fluoride particles before the mechanochemical treatment.
- the Y value was measured for each sample under a black background and a white background with a color difference meter (SE7700, manufactured by Nippon Denshoku Co., Ltd.), and the transparency was calculated according to the following formula (contrast ratio: Yb / Yw ) was calculated.
- Yb/Yw Y value (Yb) under black background/Y value (Yw) under white background.
- X-ray opaque filler As the X-ray opaque filler, crystalline rare earth metal fluoride particles (YbF 3 -40, YbF 3 -100, YbF 3 -100, YbF 3 -100, YbF 3 -200, YbF 3 -300, LaF 3 , CeF 3 and GdF 3 ), and powder obtained by subjecting these raw powders to mechanochemical treatment were used.
- Table 1 shows the abbreviations of the X-ray opaque fillers of Examples and Comparative Examples, and the crystalline rare earth metal fluoride particles (raw material powder itself, or raw material powder Mechanochemically treated powder), raw material powder mechanochemical treatment time, average primary particle size (for mechanochemically treated raw material powder, value after mechanochemical treatment), maximum peak 2 ⁇ and maximum peak FWHM and refractive index nX are shown.
- the mechanochemical treatment was performed using a wet bead mill SC50 ⁇ manufactured by Mitsui Mining Co., Ltd. ⁇ .
- a slurry obtained by mixing 5.0 parts by mass of crystalline rare earth metal fluoride particles with 100 parts by mass of ion-exchanged water was dispersed using 100 g of ⁇ 0.3 mm zirconia beads as media at a rotation speed of 3000 rpm.
- Table 1 shows the type of crystalline rare earth metal fluoride particles used in the dispersion treatment and the treatment time.
- a measurement sample obtained by removing coarse particles with a sieve having an opening of 100 ⁇ m from the raw material powder or the powder after the mechanochemical treatment was used.
- Example 1 Add 0.2 parts by weight of CQ and 0.35 parts by weight of DMBE as a polymerization initiator to 100 parts by weight of a polymerizable monomer consisting of 80 parts by weight of UDMA and 20 parts by weight of 3G, and stir for 6 hours.
- a liquid composition was prepared.
- F1 as an X-ray opaque filler was added to 100 parts by mass of the polymerizable monomer so as to be 150 parts by mass (60 wt%), and then mixed with an agate mortar.
- a pasty curable composition was obtained by defoaming the resulting mixture under vacuum to remove air bubbles. The transparency (contrast ratio) of the obtained cured product of the curable composition was evaluated. Table 2 shows the results.
- Examples 2-15, Comparative Examples 1-6 Examples 2 to 15 and Comparative Examples were prepared in the same manner as in Example 1, except that the materials shown in Table 2 were used as the polymerizable monomer, polymerization initiator, and X-ray opaque filler to be blended in Example 1. 1-6 curable compositions were prepared. Then, the transparency (contrast ratio) of the cured body of the obtained curable composition was evaluated. The results are also shown in Table 2.
- Examples 16-22, Comparative Examples 7-13 In Example 2, curable compositions of Examples 16 to 22 were prepared in the same manner as in Example 2, except that the composition of the polymerizable monomers to be blended was changed as shown in Table 3. Curable compositions of Comparative Examples 7 to 13 were prepared in the same manner as in Comparative Example 1 except that the composition of the polymerizable monomers to be blended in Example 1 was changed as shown in Table 3. Then, the obtained paste-like curable composition and its cured product were evaluated for transparency. The results are also shown in Table 3.
- the polymerizable monomer composition and the The refractive index of the cured body is different.
- the examples and comparative examples having the same polymerizable monomer composition are compared, the X-ray opaque filler having a maximum peak half width of 0.3° or more: the example using F1-3h In 16 to 22, the contrast ratios of the curable composition and the cured body are lower than in Comparative Examples 7 to 13 using the radiopaque filler: RF1, which has a maximum peak half width of less than 0.3°. It was confirmed that the transparency is high.
- the amount of the X-ray opaque filler of the present invention exhibiting X-ray opacity about the same as that of an aluminum material having the same thickness as the cured body is 100 parts by mass of the curable composition. It was about 3 to 10 parts by mass.
- the curable composition of each example described above can be suitably used as a dental curable composition.
- various graphs created based on the experimental data shown in Tables 1 to 6 are shown in FIGS. 1 to 8.
- FIG. 1 to 8 various graphs created based on the experimental data shown in Tables 1 to 6 are shown in FIGS. 1 to 8.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Plastic & Reconstructive Surgery (AREA)
- Dental Preparations (AREA)
Abstract
Description
本発明の第二の形態は、本発明のX線不透過性充填材からなることを特徴とする歯科用X線不透過性充填材(以下、「本発明の歯科用X線不透過性充填材」ともいう。)である。
・式(1) -0.02≦(nX-nM)≦0.1
〔前記式(1)中、nXは、前記結晶性希土類金属フッ化物粒子の屈折率を意味し、nMは、前記重合性単量体の硬化体の屈折率を意味する。〕
(i)上記メカノケミカル処理によって結晶粒子の結晶性が低下する。
(ii)結晶粒子の結晶性は、前記粉体のX線回折測定により得られた回折パターンにおける結晶性フッ化イッテルビウムに由来する最大強度ピークの半値全幅(最大ピーク半値幅)により把握される。そして、前記粉体の微細化が殆ど起こらないような状態であっても、結晶性低下の度合いがある程度を超えた場合、透明性低下防止効果が得られる。
(1)前記最大ピーク半値幅と硬化体の透明性(コントラスト比)との間には比較的明瞭な相関がみられたこと(後述する図1参照。)。
(2)前記最大ピーク半値幅は、メカノケミカル処理時間にほぼ比例して増大すること(後述する図2参照。)。
(3)粉体の平均1次粒子径と硬化体の透明性(コントラスト比)との間には相関がみられなかったこと(後述する図3及び図4参照。)。
(4)マトリックス樹脂(重合性単量体の硬化体)の屈折率が特定の値となる場合に限って透明性低下防止効果がみられるというわけではなく、比較的広い屈折率の範囲のマトリックス樹脂に対して上記効果がみられたこと(後述する図5~図8参照。)。
(5)前記(4)と関連して、(重合性単量体とその硬化体とでは屈折率が異なるところ)硬化を行う前のペースト状態の硬化性組成物及び硬化後の硬化体の両方で透明低下防止効果がみられたこと(後述する図5~図8参照。)。
本発明のX線不透過性充填材は、重合性単量体を含む硬化性組成物に配合することにより前記硬化性組成物及びその硬化体にX線不透過性を付与するX線不透過性充填材である。X線不透過性を付与する対象物となる硬化性組成物に含まれる重合性単量体は重合性を有する化合物であれば特に限定されず、その用途に応じて通常使用されるものが使用できる。例えば、硬化性組成物が歯科用硬化性組成物である場合には、当該用途で汎用的に使用されるラジカル重合性単量体等が使用できる。透明性の観点からは、本発明のX線不透過性充填材の配合対象となる硬化性組成物で使用される重合性単量体は、屈折率の差である「nX-nM」が特定の範囲内となる条件を満たすものであることが好ましい。ここで、nXは、本発明のX線不透過性充填材の主成分である結晶性希土類金属フッ化物粒子の屈折率を意味し、nMは、重合性単量体の硬化体の屈折率を意味する。具体的には、下式(1)を満たすことが好ましく、下式(2)を満たすことよりが好ましく、下式(3)を満たすことが最も好ましい。なお、メカノケミカル処理された結晶性希土類金属フッ化物粒子は、上述したように表面近傍に屈折率傾斜層を有すると推定される。しかしながら、メカノケミカル処理された結晶性希土類金属フッ化物粒子全体に占める屈折率傾斜層の割合は非常に小さいため、屈折率傾斜層の有無は、粒子全体の屈折率には実質的に影響しないと考えられる。また、本発明者らは、メカノケミカル処理前後における結晶性希土類金属フッ化物粒子の屈折率には実質的に有意な差が存在しないことを確認した。したがって、X線不透過性充填材の主成分である結晶性希土類金属フッ化物粒子がメカノケミカル処理されたものか否かを問わず、式(1)~(3)に示す屈折率差「nX-nM」の計算に際しては、屈折率nXとして、便宜上、メカノケミカル処理前の結晶性希土類金属フッ化物粒子の屈折率を測定して得られた値を用いた。
・式(1) -0.02≦(nX-nM)≦0.1
・式(2) -0.01≦(nX-nM)≦0.07
・式(3) 0≦(nX-nM)≦0.05
結晶性希土類金属フッ化物粒子における希土類金属フッ化物としては、その色調や安全性からフッ化ランタン(LaF3)、フッ化セリウム(CeF3)、フッ化イッテルビウム(YbF3)、又は、フッ化ガドリニウム(GdF3)を使用することが好ましく、X線不透過性の観点からフッ化イッテルビウム(YbF3)を使用することが最も好ましい。結晶性希土類金属フッ化物粒子の結晶構造は特に限定されず、通常は、希土類金属フッ化物の種類に応じて、常温常圧で安定な結晶構造のものが使用される。なお、これら結晶性希土類金属フッ化物の25℃におけるナトリウムd線に対する屈折率は、通常、1.50~1.65の範囲である。
本発明のX線不透過性充填材においては、不透明化防止効果を得るために、最大ピーク半値幅、すなわち前記粉体のX線回折パターンにおける前記結晶性希土類金属フッ化物粒子に由来する最大強度ピークの半値全幅、が0.3°以上である必要がある。不透明化防止効果の高さの観点から、最大ピーク半値幅は、0.4°以上であることが好ましく、特に0.5°以上であることが好ましい。なお、最大ピーク半値幅の上限値は特に限定されないが通常は、40°を超えることはない。但し、後述する表1を踏まえれば、本実施形態のX線不透過性充填材の生産性(メカノケミカル処理時間)の観点から、最大ピーク半値幅は0.77°以下であることが好ましい。また、硬化体の透明性とX線不透過性充填材の生産性とをよりバランス良く両立させる観点から、最大ピーク半値幅は、0.47°~0.68°が好ましく、0.51°~0.59°がさらに好ましい。
本発明の製造方法は、本発明のX線不透過性充填材を製造する方法であって、結晶性希土類金属フッ化物粒子を主成分として含み、且つ、最大ピーク半値幅が0.3°未満である原料粉体をメカノケミカル処理して、最大ピーク半値幅を0.3°以上とする工程を含むことを特徴とする。
先に述べたように、本発明のX線不透過性充填材は、歯科用硬化性組成物に配合される充填材(すなわち、歯科用X線不透過性充填材)として特に有用である。歯科用硬化性組成物には、本発明のX線不透過性充填材に加えて、重合性単量体と重合開始剤とが配合される。
本発明の歯科用硬化性組成物にその他の充填材を配合する場合の配合量も、歯科用硬化性組成物がペースト状となる範囲であれば特に限定されない。しかし、歯科用硬化性組成物を歯科用充填修復材料として用いる場合には、X線不透過性充填材とその他の充填剤との合計量が、重合性単量体100質量部に対して、25~400質量部であることが好ましく、40~250質量部とすることがより好ましい。
1-1.重合性単量体
UDMA:1,6-ビス(メタクリルエチルオキシカルボニルアミノ)-2,2,4-トリメチルヘキサン
3G:トリエチレングリコールジメタクリレート
BisGMA:2,2-ビス[4-[2-ヒドロキシ-3-(メタクリロイルオキシ)プロピルオキシ]フェニル]プロパン
D-2.6E:2,2-ビス[4-(メタクリロキシエトキシ)フェニル]プロパン
CQ:カンファーキノン(東京化成工業株式会社製)
DMBE:ジメチル安息香酸エチル(東京化成工業株式会社製)
(1)結晶性希土類金属フッ化物粒子(原料粉体)
X線不透過性充填材の原材料(原料粉体)としては下記に示す結晶性希土類金属フッ化物粒子を用いた。
RF1:YbF3-40(平均1次粒子径40nm、平均2次粒子径0.6μm、屈折率1.55のフッ化イッテルビウム、Sukgyung社製)
RF2:YbF3-100(平均1次粒子径100nm、平均2次粒子径0.6μm、屈折率1.55のフッ化イッテルビウム、Sukgyung社製)
RF3:YbF3-200(平均1次粒子径200nm、平均2次粒子径0.6μm、屈折率1.55のフッ化イッテルビウム、Treibacher社製)
RF4:YbF3-300(平均1次粒子径300nm、平均2次粒子径0.6μm、屈折率1.55のフッ化イッテルビウム、Treibacher社製)
RF5:LaF3(平均1次粒子径400nm、平均2次粒子径0.6μm、屈折率1.58のフッ化ランタン、富士フィルム和光純薬株式会社製)
RF6:CeF3(平均1次粒子径350nm、平均2次粒子径0.7μm、屈折率1.63のフッ化セリウム、富士フィルム和光純薬株式会社製)
RF7:GdF3(平均1次粒子径390nm、平均2次粒子径0.6μm、屈折率1.62のフッ化ガドリニウム、富士フィルム和光純薬株式会社製)
なお、平均1次粒子径、平均2次粒子径及び屈折率は、後述の評価方法に基づき決定された値である。
2-1.平均1次粒子径の測定
X線不透過性充填材を構成する結晶性希土類金属フッ化物粒子の平均1次粒子径は、走査型電子顕微鏡を用いて以下の手順により求めた。まず、X線不透過性充填材を試料台上にカーボンペーストで固定した後に、導電処理(白金蒸着)を施した測定用試料を準備した。次に、この測定用試料を、電子顕微鏡(JSM-7800F PRIME、日本電子株式会社製)にて100,000倍の倍率で観察し、得られた観察像中の1次粒子100個の平均粒子径を平均1次粒子径として求めた。また、同様の手順により原料粉体の平均一次粒子径も求めた。
X線不透過性充填材を構成する結晶性希土類金属フッ化物粒子の平均2次粒子径は粒度分布測定により以下の手順で求めた。まず、0.1gの粉体(X線不透過性充填材)をイオン交換水10mLに懸濁した懸濁液を準備した。次に、この懸濁液を超音波照射した状態で、粒度分布計(LS13-320、BECKMAN COULTER社製)を用いて粒度分布測定を行い、体積粒度分布を得た。そして、体積粒度分布の小径側から累積50%となる粒子径(D50v値)をX線不透過性充填材を構成する結晶性希土類金属フッ化物粒子の平均2次粒子径とした。また、同様の手順により原料粉体の平均2次粒子径も求めた。
2-3-1.重合性単量体の屈折率n0
硬化性組成物の調製に使用した重合性単量体の屈折率n0は、アッベ屈折率計(DR-A1-Plus、株式会社アタゴ社製)を用いて、25℃においてナトリウムd線に対する屈折率として測定した。
硬化性組成物の調製に使用した重合性単量体(但し、硬化処理のために微量の重合開始剤(0.2重量%のカンファーキノン及び0.35重量%のN,N-ジメチル-p-安息香酸エチル)を含む)を、型に設けられた貫通孔(直径7mm、貫通孔長さ0.5mm)に充填した後、貫通孔の両側開口部をポリプロピレンフィルムで圧接しながら封止した。その後、貫通孔内に充填された重合性単量体に対して、光量500mW/cm2のハロゲン型歯科用光照射器(Demetron LC、サイプロン社製)を用いて30秒間光照射することで硬化させた。その後、型から取り出した重合性単量体の硬化体について、2-3-1と同様の手順で屈折率nMを測定した。
25℃の恒温室において、100mLのサンプル瓶中、結晶性希土類フッ化物粒子1gを無水トルエン50mL中に懸濁した。この懸濁液をスターラーで撹拌しながら1-ブロモトルエンを少しずつ滴下し、懸濁液が最も透明となった時点の懸濁液の屈折率を2-3-1と同様の手順で測定し、得られた値を結晶性希土類フッ化物粒子の屈折率nXとした。なお、既述したように、メカノケミカル処理後の結晶性希土類フッ化物粒子の屈折率nXは、メカノケミカル処理前の結晶性希土類フッ化物粒子の屈折率で代用した。
各実施例及び比較例で調製した硬化性組成物を、内径0.7cm、深さ0.1cmのポリアセタール製モールドに充填した。硬化性組成物の透明性を評価する場合には、このモールドを試料とした。また、硬化体の透明性を評価する場合には、上記と同様にモールド内に硬化性組成物を充填した後に歯科用の光照射器(TOKUSO POWER LIGHT、株式会社トクヤマ社製)を用い、照射距離0.5cmで20秒間光照射して硬化させたものを試料とした。透明性の評価は、各試料について色差計(SE7700、株式会社日本電色社製)にて黒背景及び白背景下にてY値を測定し、下式により透明性(コントラスト比:Yb/Yw)を算出した。
X線不透過性充填材としては、1-3(1)に原料粉体として列挙した結晶性希土類金属フッ化物粒子(YbF3―40、YbF3-100、YbF3―200、YbF3-300、LaF3、CeF3及びGdF3)、及び、これら原料粉体についてメカノケミカル処理を行った粉体を使用した。表1に、実施例及び比較例のX線不透過性充填材の略号、X線不透過性充填材の製造に使用した結晶性希土類金属フッ化物粒子(原料粉体そのもの、または、原料粉体をメカノケミカル処理した粉体)の略号、原料粉体のメカノケミカル処理時間、平均1次粒子径(メカノケミカル処理した原料粉体についてはメカノケミカル処理後の値)、最大ピークの2θ及び最大ピーク半値幅、ならびに、屈折率nXを示す。
実施例1
80質量部のUDMA及び20質量部の3Gからなる重合性単量体100質量部に対して、重合開始剤として0.2重量部のCQ及び0.35重量部のDMBEを加え、6時間撹拌し液状組成物を調製した。この液状組成物に対して、X線不透過性充填材としてF1を重合性単量体100質量部に対して、150質量部(60wt%)となるように加えた後、メノウ乳鉢で混合し、得られた混合物を真空下にて脱泡して気泡を取り除くことにより、ペースト状の硬化性組成物を得た。得られた硬化性組成物の硬化体について、透明性(コントラスト比)を評価した。結果を表2に示した。
実施例1において、配合する重合性単量体、重合開始剤及びX線不透過性充填材として表2に示す材料を用いた以外は実施例1と同様にして実施例2~15及び比較例1~6の硬化性組成物を調製した。そして、得られた硬化性組成物の硬化体の透明性(コントラスト比)を評価した。結果を併せて表2に示した。
実施例2において、配合する重合性単量体の組成を表3に記載したように変更した以外は実施例2と同様にして実施例16~22の硬化性組成物を調製し、また、比較例1において、配合する重合性単量体の組成を表3に記載したように変更した以外は比較例1と同様にして比較例7~13の硬化性組成物を調製した。そして、得られたペースト状の硬化性組成物及びその硬化体の透明性を評価した。結果を併せて表3に示した。
用いたX線不透過性充填材をF5-3h(LaF3)及びRF5(LaF3)に変更した以外は実施例16~22及び比較例7~13と同様にして、実施例23~29及び比較例14~20の硬化性組成物を調製した。そして、得られたペースト状の硬化性組成物及びその硬化体の透明性を評価した。結果を併せて表4に示した。
用いたX線不透過性充填材をF6-3h(CeF3)及びRF6(CeF3)に変更した以外は実施例16~22及び比較例7~13と同様にして、実施例30~36及び比較例21~27の硬化性組成物を調製した。そして、得られたペースト状の硬化性組成物及びその硬化体の透明性を評価した。結果を併せて表5に示した。
用いたX線不透過性充填材をF7-3h(GdF3)及びRF7(GdF3)に変更した以外は実施例16~22及び比較例7~13と同様にして、実施例37~43及び比較例28~34の硬化性組成物を調製した。そして、得られたペースト状の硬化性組成物及びその硬化体の透明性を評価した。結果を併せて表6に示した。
各実施例の硬化性組成物についてISO13116-2014に準じて試験を行った。その結果、いずれの実施例の硬化性組成物から得られた硬化体においても、当該硬化体と同一の厚みを有するアルミニウム材を上回るX線不透過性を示した。よって、いずれの実施例の硬化性組成物から得られた硬化体も、X線に対して十分な不透過性を有することが確認された。なお、歯科材料として必要とされる実用的なX線不透過性は、硬化体と同一の厚みを有するアルミニウム材と同等程度前後あるいはそれ以上のX線不透過性を示すことが必要である。ここで、硬化体と同一の厚みを有するアルミニウム材と同等程度前後のX線不透過性を示す本発明のX線不透過性充填材の配合量は、硬化性組成物100質量部に対して概ね3~10質量部程度であった。
Claims (13)
- 重合性単量体を含む硬化性組成物に配合することにより前記硬化性組成物及びその硬化体にX線不透過性を付与するX線不透過性充填材であって、
結晶性希土類金属フッ化物粒子を主成分として含み、且つ、X線回折パターンにおける前記結晶性希土類金属フッ化物粒子に由来する最大強度ピークの半値全幅が0.3°以上である第1の粉体、及び、前記第1の粉体を表面処理した第2の粉体からなる群より選択されるいずれかの粉体からなる、
ことを特徴とするX線不透過性充填材。 - 前記第1の粉体が、電子顕微鏡によって測定される平均1次粒子径が1~500nmである結晶性希土類金属フッ化物粒子、及び、前記平均1次粒子径が1~500nmである結晶性希土類金属フッ化物粒子の凝集粒子、からなる群より選択される少なくとも一方の粒子を主成分として含む粉体である、請求項1に記載のX線不透過性充填材。
- 前記結晶性希土類金属フッ化物粒子が、結晶性フッ化イッテルビウム粒子である、請求項1又は2に記載のX線不透過性充填材。
- 前記結晶性希土類金属フッ化物粒子が、結晶性フッ化ランタン粒子、結晶性フッ化セリウム粒子、及び、結晶性フッ化ガドリニウム粒子、からなる群より選択される少なくとも1種の粒子を含む、請求項1又は2に記載のX線不透過性充填材。
- 前記半値全幅が0.77°以下である、請求項1~4のいずれか1項に記載のX線不透過性充填材。
- 前記半値全幅が0.47°~0.68°である、請求項1~4のいずれか1項に記載のX線不透過性充填材。
- 前記半値全幅が0.51°~0.59°である、請求項1~4のいずれか1項に記載のX線不透過性充填材。
- 請求項1~7のいずれか1項に記載のX線不透過性充填材からなることを特徴とする歯科用X線不透過性充填材。
- 請求項1~7のいずれか1項に記載のX線不透過性充填材を製造する方法であって、
結晶性希土類金属フッ化物粒子を主成分として含み、且つ、X線回折パターンにおける前記結晶性希土類金属フッ化物粒子に由来する最大ピークの半値全幅が0.3°未満である原料粉体をメカノケミカル処理して、前記半値全幅を0.3°以上とする工程を含む、
ことを特徴とするX線不透過性充填材の製造方法。 - 前記メカノケミカル処理が湿式ビーズミル処理である、請求項9に記載のX線不透過性充填材の製造方法。
- 重合性単量体及び請求項1~8のいずれか1項に記載のX線不透過性充填材を含むことを特徴とする歯科用硬化性組成物。
- 前記結晶性希土類金属フッ化物粒子が、結晶性フッ化イッテルビウム粒子であり、前記重合性単量体の硬化体の25℃におけるナトリウムd線に対する屈折率が1.45~1.60である、請求項11に記載の歯科用硬化性組成物。
- 下式(1)を満たす請求項11または12に記載の歯科用硬化性組成物。
・式(1) -0.02≦(nX-nM)≦0.1
〔前記式(1)中、nXは、前記結晶性希土類金属フッ化物粒子の屈折率を意味し、nMは、前記重合性単量体の硬化体の屈折率を意味する。〕
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA3227331A CA3227331A1 (en) | 2021-09-14 | 2022-08-18 | X-ray opaque filler, dental x-ray opaque filler, method of producing the x-ray opaque filler, and dental curable composition |
KR1020247000381A KR20240060585A (ko) | 2021-09-14 | 2022-08-18 | X선 불투과성 충전재, 치과용 x선 불투과성 충전재, x선 불투과성 충전재의 제조 방법, 및 치과용 경화성 조성물 |
JP2023548369A JPWO2023042598A1 (ja) | 2021-09-14 | 2022-08-18 | |
CN202280047439.2A CN117642143A (zh) | 2021-09-14 | 2022-08-18 | X射线非穿透性填料、牙科用x射线非穿透性填料、x射线非穿透性填料的制造方法及牙科用硬化性组合物 |
AU2022345585A AU2022345585A1 (en) | 2021-09-14 | 2022-08-18 | X-ray opaque filler material, x-ray opaque dental filler material, method for producing x-ray opaque filler material, and curable dental composition |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2021-149210 | 2021-09-14 | ||
JP2021149210 | 2021-09-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023042598A1 true WO2023042598A1 (ja) | 2023-03-23 |
Family
ID=85602125
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2022/031237 WO2023042598A1 (ja) | 2021-09-14 | 2022-08-18 | X線不透過性充填材、歯科用x線不透過性充填材、x線不透過性充填材の製造方法、及び、歯科用硬化性組成物 |
Country Status (6)
Country | Link |
---|---|
JP (1) | JPWO2023042598A1 (ja) |
KR (1) | KR20240060585A (ja) |
CN (1) | CN117642143A (ja) |
AU (1) | AU2022345585A1 (ja) |
CA (1) | CA3227331A1 (ja) |
WO (1) | WO2023042598A1 (ja) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5651407A (en) * | 1979-09-28 | 1981-05-09 | Colgate Palmolive Co | Radiation impermeable dental composition |
JPH0317803B2 (ja) * | 1985-01-26 | 1991-03-11 | Etaburisemento Dentaia Ifuokuraa | |
JP2008266767A (ja) * | 2007-03-29 | 2008-11-06 | Hitachi Chem Co Ltd | フッ化物コート膜形成処理液およびフッ化物コート膜形成方法 |
JP2021080196A (ja) * | 2019-11-18 | 2021-05-27 | クラレノリタケデンタル株式会社 | 歯科用組成物 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0317803A (ja) | 1989-06-14 | 1991-01-25 | Pioneer Electron Corp | 磁気記録再生装置 |
-
2022
- 2022-08-18 JP JP2023548369A patent/JPWO2023042598A1/ja active Pending
- 2022-08-18 CN CN202280047439.2A patent/CN117642143A/zh active Pending
- 2022-08-18 WO PCT/JP2022/031237 patent/WO2023042598A1/ja active Application Filing
- 2022-08-18 CA CA3227331A patent/CA3227331A1/en active Pending
- 2022-08-18 KR KR1020247000381A patent/KR20240060585A/ko unknown
- 2022-08-18 AU AU2022345585A patent/AU2022345585A1/en active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5651407A (en) * | 1979-09-28 | 1981-05-09 | Colgate Palmolive Co | Radiation impermeable dental composition |
JPH0317803B2 (ja) * | 1985-01-26 | 1991-03-11 | Etaburisemento Dentaia Ifuokuraa | |
JP2008266767A (ja) * | 2007-03-29 | 2008-11-06 | Hitachi Chem Co Ltd | フッ化物コート膜形成処理液およびフッ化物コート膜形成方法 |
JP2021080196A (ja) * | 2019-11-18 | 2021-05-27 | クラレノリタケデンタル株式会社 | 歯科用組成物 |
Non-Patent Citations (1)
Title |
---|
HASEBE, RUI; TERUO NAMBA: "Development of fluoride fillers for dental material applications", SERAMIKKUSU = CERAMICS JAPAN : BULLETIN OF THE CERAMIC SOCIETY OF JAPAN, NIPPON SERAMIKKUSU KYOKAI, TOKYO, JP, vol. 54, no. 9, 1 January 2019 (2019-01-01), JP , pages 646 - 649, XP009544536, ISSN: 0009-031X * |
Also Published As
Publication number | Publication date |
---|---|
KR20240060585A (ko) | 2024-05-08 |
JPWO2023042598A1 (ja) | 2023-03-23 |
CA3227331A1 (en) | 2023-03-23 |
CN117642143A (zh) | 2024-03-01 |
AU2022345585A1 (en) | 2024-01-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60115194T2 (de) | Photohärtbares material für zahnreparaturen | |
EP2724706B1 (en) | Dental restorative material | |
CN102327194B (zh) | 包括酪蛋白酸盐的牙科组合物和制备牙科制品的方法 | |
JP5769429B2 (ja) | 歯科用複合修復材料 | |
CA2077734C (en) | Dental filling composition | |
JP3487395B2 (ja) | 硬化性組成物 | |
WO2011158742A1 (ja) | 歯科用複合修復材料 | |
JP5094188B2 (ja) | 歯科用硬化性組成物 | |
EP3682862A1 (en) | Curable dental composition | |
JP4895443B2 (ja) | 歯科用硬化性組成物 | |
JP2007314484A (ja) | 歯科用有機無機複合フィラー、該フィラーを用いた歯科用修復材組成物及びそれらの製造方法 | |
WO2020050123A1 (ja) | 複合材料、硬化性組成物、及び硬化性組成物の製造方法 | |
JP7350248B2 (ja) | 有機無機複合フィラーの製造方法、および歯科用硬化性組成物の製造方法 | |
WO2023042598A1 (ja) | X線不透過性充填材、歯科用x線不透過性充填材、x線不透過性充填材の製造方法、及び、歯科用硬化性組成物 | |
JPH0312044B2 (ja) | ||
JP2023118513A (ja) | X線不透過性充填材、x線不透過性充填材の製造方法、硬化性組成物および歯科用硬化性組成物 | |
JPH0461003B2 (ja) | ||
WO2023085201A1 (ja) | 歯科用硬化性組成物 | |
RU2821202C1 (ru) | Отверждаемая композиция для стоматологии | |
JP3520694B2 (ja) | 硬化性組成物 | |
JP7430560B2 (ja) | 歯科用充填用組成物および二剤型歯科用充填剤 | |
WO2021131476A1 (ja) | 歯科用硬化性組成物 | |
JP2021113163A (ja) | 歯科用硬化性組成物 | |
JP2023107373A (ja) | 歯科用硬化性組成物 | |
JP2022097349A (ja) | 有機無機複合フィラー及びその製造方法並びに該有機無機複合フィラーを含有する歯科用硬化性組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22869745 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 202280047439.2 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2022345585 Country of ref document: AU Ref document number: 2023548369 Country of ref document: JP Ref document number: AU2022345585 Country of ref document: AU |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112024000126 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 2022345585 Country of ref document: AU Date of ref document: 20220818 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 3227331 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 112024000126 Country of ref document: BR Kind code of ref document: A2 Effective date: 20240104 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2022869745 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2022869745 Country of ref document: EP Effective date: 20240415 |